Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Safety Tolerability Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to

  • 15 views
  • 02 Jun, 2021
  • 21 locations
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the investigator

measurable disease
orchiectomy
liver metastases
testosterone
metastatic prostate cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Lung Cancer With Copanlisib and Durvalumab

with a goal of cure. The overall hypothesis of this study is that the addition of Copanlisib to Durvalumab will be well-tolerated at a biweekly schedule. It will test whether the addition of Copanlisib

measurable disease
lung carcinoma
durvalumab
stage iii non-small cell lung cancer
  • 0 views
  • 29 May, 2021
  • 1 location
Study of Copanlisib and Ketogenic Diet

This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies

  • 0 views
  • 17 Feb, 2021
  • 3 locations
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

also being done to find out the highest doses of copanlisib and vemurafenib that, when given in combination, do not cause serious side effects, and whether the study treatment will make radioiodine

BRAF
measurable disease
absolute neutrophil count
avid
gilbert's syndrome
  • 0 views
  • 25 Mar, 2021
  • 7 locations
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

. The PI3K inhibitor Copanlisib has shown high clinical activity in indolent B - cell lymphomas among them MZL. Based on these observations it is the aim of this study to test the toxicity and efficacy

measurable disease
platelet count
interferon
gastric malt lymphoma
chlorambucil
  • 9 views
  • 05 Feb, 2021
  • 23 locations
A Study of a New Drug Combination Copanlisib and Fulvestrant in Advanced Breast Cancer

This phase I/II trial studies the side effects and how well copanlisib works when given together with fulvestrant in treating patients with estrogen receptor positive (ER+) and human epidermal

  • 0 views
  • 15 May, 2021
  • 2 locations
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

This is a prospective, multicenter, non-randomized, open-label, phase II study to describe the efficacy of R-CHOP plus copanlisib including a safety run-in phase in order to detect early and

b-cell lymphoma
platelet count
rituximab
gilbert's syndrome
follicular lymphoma
  • 0 views
  • 26 Jan, 2021
  • 6 locations
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

This is a multicentric single arm phase II trial, to investigate the efficacy (in terms of PFS) of the combination regimen rituximab-bendamustine in association with copanlisib in patients

  • 0 views
  • 26 May, 2021
  • 28 locations